CIN: L24231TN1990PLC019053

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

PRESS RELEASE

Gross Revenue up 45%, PAT up 59%

Results - Q4 FY 15 and FY 2015

Chennai, August 20, 2015: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) today reported its financial results for the Quarter (Q4 FY 15) and year ending June 30, 2015 (FY15)

Key Financial & Performance Highlights - Consolidated

INR Lacs

Details	Q4 FY 15	Q4 FY 14	Growth	FY 15	FY 14	Growth
Gross Revenue	7,013	4,801	46%	25,177	17,309	45%
EBITDA	1,970	1,047	88%	6,200	3,935	58%
EBITDA %	28%	22%		25%	23%	
PAT	1,269	698	82%	4,104	2,585	59%
PAT %	18%	15%		16%	15%	

Key Financial & Performance Highlights - Standalone

+9197884 59333/69333

INR Lacs

Details	Q4 FY 15	Q4 FY 14	Growth	FY 15	FY 14	Growth
Gross Revenue	6,755	4,593	47%	24,023	16,640	44%
EBITDA	1,936	991	95%	5,930	3,694	61%
EBITDA %	29%	22%		25%	22%	
PAT	1,270	693	83%	4,094	2,564	60%
PAT %	19%	15%		17%	15%	

The company's topline, EBIDTA and PAT have all strengthened considerably compared to the previous financial year. Company has completed 173 product registrations in existing markets and another 63 in new markets, in the last 12 months. Approval for another 400 products are expected in the next 3-4 Quarters, taking the total number of product registrations to over 2000 altogether. Addition of Softgel, Penem and Suppository lines are expected to boost sales further in the near term, for emerging markets.

The company was, for the second consecutive year, selected under the Forbes Asia's "200 Best under a Billion" list for 2015.



CIN: L24231TN1990PLC019053

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone = +91 44 28156653. 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

Regulated Markets

Company has already received approval from EU-GMP for Unit-IV and awaiting Brazil's ANVISA GMP approval shortly. Company is expected to file their first 3 ANDAs for US in 2016, and plans are in place for more filings in future.

R&D

Total R&D spend for FY 2015 has more than tripled to INR 761 lacs compared to previous corresponding year's spend of INR 233 lacs. This constitutes to around 19% of PAT, spent on R&D. Company expects to further invest a sizeable figure into R&D, going forward. The company has also doubled the number of scientists at R&D, compared to the previous year.

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa.

Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company currently holds over 1600 product licenses across Latin America and Africa with another 400 in the pipeline. The company is poised to enter into the regulated markets for injectables, in the near future.

Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.